EPHX2 and breast cancer: Nevertheless, the benefits of sEH inhibition in DOX-treated cancer patients should be carefully evaluated, since a group of researchers demonstrated that levels of 14,15-EET increased in breast cancer tissues compared to adjacent noncancerous tissue and that overexpression of sEH attenuated proliferation and migration in human breast cancer cells [38].